Claims
- 1. A method for inhibiting P-glycoprotein comprising administering to a mammal in need of such treatment an amount of lopinavir effective to inhibit P-glycoprotein.
- 2. The method of claim 1 wherein the step of administering comprises administering a pharmaceutical composition comprising lopinavir.
- 3. The method of claim 1 further comprising administering ritonavir or a therapeutically acceptable salt thereof.
- 4. The method of claim 3 wherein the step of administering ritonavir comprises administering a pharmaceutical composition comprising ritonavir.
- 5. The method of claim 1, wherein the mammal is a human.
- 6. A method for enhancing the bioavailability of a pharmaceutically active agent comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of the pharmaceutically active agent.
- 7. The method of claim 6 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 8. The method of claim 6, wherein the step of co-administering further comprises administering ritonavir or a therapeutically acceptable salt thereof.
- 9. The method of claim 8 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 10. The method of claim 6 wherein the mammal is a human.
- 11. A method for increasing the central nervous system penetration of a pharmaceutically active agent comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of the pharmaceutically active agent.
- 12. The method of claim 11 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 13. The method of claim 11 wherein the step of co-administering further comprises administering ritonavir or a therapeutically acceptable salt thereof.
- 14. The method of claim 13 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 15. The method of claim 11 wherein the mammal is a human.
- 16. A method for increasing absorption of a pharmaceutically active agent from a gastrointestinal tract comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of the pharmaceutically active agent.
- 17. The method of claim 16 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 18. The method of claim 16 further comprising administering ritonavir or a therapeutically acceptable salt thereof.
- 19. The method of claim 18 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 20. The method of claim 16 wherein the mammal is a human.
- 21. A method for treating multidrug resistance comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of a pharmaceutically active agent useful to treat the multidrug resistance.
- 22. The method of claim 21 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 23. The method of claim 21 wherein the step of co-administering further comprises administering ritonavir or a therapeutically acceptable salt thereof.
- 24. The method of claim 23 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 25. The method of claim 21 wherein the mammal is a human.
- 26. A method for treating cancer comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of an anticancer agent.
- 27. The method of claim 26 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 28. The method of claim 26 further comprising co-administering ritonavir or a therapeutically acceptable salt thereof.
- 29. The method of claim 28 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 30. The method of claim 26 wherein the mammal is a human.
- 31. A method for treating a viral infection comprising co-administering to a mammal in need of such treatment a combination of an amount of lopinavir effective to inhibit P-glycoprotein and a therapeutically effective amount of an antiviral agent.
- 32. The method of claim 31 wherein the step of co-administering comprises administering at least one pharmaceutical composition comprising lopinavir.
- 33. The method of claim 31 wherein the step of co-administering further comprises administering ritonavir or a therapeutically acceptable salt thereof.
- 34. The method of claim 33 wherein the step of administering ritonavir comprises administering at least one pharmaceutical composition comprising ritonavir or a therapeutically acceptable salt thereof.
- 35. The method of claim 31 wherein the mammal is a human.
- 36. The method of claim 31 wherein the viral infection is HIV.
- 37. A pharmaceutical composition useful for treating cancer in a mammal comprising lopinavir and a pharmaceutically active anticancer agent.
- 38. The pharmaceutical composition of claim 37 further comprising ritonavir or a therapeutically acceptable salt thereof.
- 39. The pharmaceutical composition of claim 37 wherein the anticancer agent is a taxane.
- 40. The pharmaceutical composition of claim 39 wherein the taxane is paclitaxel.
- 41. The pharmaceutical composition of claim 37 wherein the anticancer agent is a spindle poison.
- 42. The pharmaceutical composition of claim 37 wherein the anticancer agent is an epidophylloptoxin.
- 43. The pharmaceutical composition of claim 37 wherein the anticancer agent is an antibiotic.
Parent Case Info
[0001] This application claims priority to provisional application Serial No. 60/367,353 which was filed on May 1, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60367353 |
May 2001 |
US |